Loading…
TARO-VALSARTAN is a brand name for Valsartan, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
, Following Myocardial Infarction). TARO-VALSARTAN 80 mg tablets TARO-VALSARTAN tablets, 80 mg are pink coloured, film-coated, round-shaped tablets with beveled edges, debossed with V5 on one side and plain on the other side. TARO-VALSARTAN 80 mg tablets are supplied in bottles of 100 and 500 tablets and blisters of 10 tablets.
TARO-VALSARTAN 160 mg tablets TARO-VALSARTAN tablets, 160 mg are orange coloured, film-coated, oval-shaped tablets with beveled edges, debossed with V6 on one side and plain on the other side. PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 8 of 45 TARO-VALSARTAN 160 mg tablets are supplied in bottles of 100 and 500 tablets and blisters of 10 tablets.
7. WARNINGS AND PRECAUTIONS Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. General Angioedema Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan: some of these patients previously experienced angioedema with other drugs including ACE inhibitors.
TARO-VALSARTAN should be immediately discontinued in patients who develop angioedema, and valsartan should not be re-administered. If laryngeal stridor or angioedema of the face, extremities, lips, tongue, or glottis occurs, TARO- VALSARTAN should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears.
In instances where swelling is confined to the face and lips, the condition generally resolves without treatment, although antihistamines may be useful in relieving symptoms. 5 ml of subcutaneous epinephrine solution 1:1000) should be administered promptly (see 8 ADVERSE REACTIONS - Post Market Findings).
Patients with a known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated with TARO-VALSARTAN (see 8 ADVERSE REACTIONS, Post Market Findings). Cardiovascular Hypotension Occasionally, symptomatic hypotension has occurred after administration of valsartan, in some cases after the first dose.
It is more likely to occur in patients who are volume -depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. In these patients, because of the potential fall in blood pressure, therapy should be started under close medical supervision.
Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. Caution should be exercised when initiating therapy after acute myocardial infarction.
Patients with heart failure or those in the early post-myocardial infarction period that are given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy is usually not necessary if patients are well screened prior to instituting treatment and found to be clinically stable.
Post Market Findings). Patients with a known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated with TARO-VALSARTAN (see 8 ADVERSE REACTIONS, Post Market Findings). Cardiovascular Hypotension Occasionally, symptomatic hypotension has occurred after administration of valsartan, in some cases after the first dose.
It is more likely to occur in patients who are volume -depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. In these patients, because of the potential fall in blood pressure, therapy should be started under close medical supervision.
Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. Caution should be exercised when initiating therapy after acute myocardial infarction.
Patients with heart failure or those in the early post-myocardial infarction period that are given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy is usually not necessary if patients are well screened prior to instituting treatment and found to be clinically stable.
If symptomatic hypotension does occur, consideration should be given to dosage reduction (see 4 DOSAGE AND ADMINISTRATION - Following Myocardial Infarction). In patients treated following myocardial infarction, the recommended regimen of valsartan has been observed to result in a greater incidence of hypotension as a serious adverse event than PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 9 of 45 the conventional dosage regimen of captopril in this indication (see 8 ADVERSE REACTIONS - Following Myocardial Infarction).
In patients with heart failure, a greater incidence of hypotension has been reported. Monitoring and dose adjustment should be considered. Valvular Stenosis There is concern on theoretical grounds that patients with aortic stenosis might be at a particular risk of decreased coronary perfusion, because they do not develop as much afterload reduction.
, Driving and Operating Machinery 01/2024 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1. INDICATIONS ...................................................................................................................
1 Pediatrics........................................................................................................................ 2 Geriatrics ........................................................................................................................
4 2. CONTRAINDICATIONS ...................................................................................................... 4 3. SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................. 5 4.
DOSAGE AND ADMINISTRATION ...................................................................................... 1 Dosing Considerations.....................................................................................................
2 Recommended Dose and Dosage Adjustment .................................................................. 5 Missed Dose ...................................................................................................................
6 5. OVERDOSAGE .................................................................................................................. 6 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 7 7. WARNINGS AND PRECAUTIONS .......................................................................................
1 Special Populations). 4. 1 Dosing Considerations • Hepatic Impairment: No initial dosage adjustment is required in patients with mild to moderate liver disease. 3 Pharmacokinetics, and 7 WARNINGS AND PRECAUTIONS - Hepatic/Biliary/Pancreatic).
• Renal Impairment: No initial dosage adjustment is required for patients with renal impairment including those patients requiring hemodialysis. 3 Pharmacokinetics, and WARNINGS AND PRECAUTIONS - Renal). 4 Geriatrics). • Concomitant Diuretic Therapy: In patients receiving diuretics, TARO-VALSARTAN therapy should be initiated with caution, since these patients may be volume -depleted and thus more likely to experience hypotension following initiation of additional anti-hypertensive therapy.
Whenever possible, all diuretics should be discontinued two to three days prior to the administration of TARO-VALSARTAN to reduce the likelihood of hypotension (see 7 WARNINGS AND PRECAUTIONS - Hypotension, and 9 DRUG INTERACTIONS - Diuretics).
If this is not possible because of the patient’s condition, TARO-VALSARTAN should be administered with caution and the blood pressure monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient.
2 Recommended Dose and Dosage Adjustment • Hypertension PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 6 of 45 Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and other pertinent clinical factors ( see 7 WARNINGS AND PRECAUTIONS- Hypotension).
The dosage of antihypertensive agents used with TARO-VALSARTAN may need to be adjusted. The recommended initial dose of TARO-VALSARTAN is 80 mg once daily. The antihypertensive effect is present within 2 weeks and maximal reduction is usually attained within 4 weeks following initiation of therapy.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Valsartan in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
If symptomatic hypotension does occur, consideration should be given to dosage reduction (see 4 DOSAGE AND ADMINISTRATION - Following Myocardial Infarction). In patients treated following myocardial infarction, the recommended regimen of valsartan has been observed to result in a greater incidence of hypotension as a serious adverse event than PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 9 of 45 the conventional dosage regimen of captopril in this indication (see 8 ADVERSE REACTIONS - Following Myocardial Infarction).
In patients with heart failure, a greater incidence of hypotension has been reported. Monitoring and dose adjustment should be considered. Valvular Stenosis There is concern on theoretical grounds that patients with aortic stenosis might be at a particular risk of decreased coronary perfusion, because they do not develop as much afterload reduction.
73m2). Therefore, the use of TARO-VALSARTAN in combination with aliskiren-containing drugs is contraindicated in these patients. Co- administration of ARBs, including TARO-VALSARTAN, with other agents blocking the RAS such as ACEIs or aliskiren-containing drugs is not recommended in any patient, as adverse outcomes cannot be excluded.
Driving and Operating Machinery Exercise caution when driving or operating a vehicle or potentially dangerous machinery. Hepatic/Biliary/Pancreatic On average, patients with mild to moderate chronic liver disease have twice the exposure to valsartan of healthy volunteers as measured by AUC and Cmax.
3 Pharmacokinetics). Renal As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death.
In susceptible patients, concomitant diuretic use may further increase risk. Following myocardial infarction, major renal dysfunction was observed to occur more frequently with valsartan than with captopril […]
73m2). Therefore, the use of TARO-VALSARTAN in combination with aliskiren-containing drugs is contraindicated in these patients. Co- administration of ARBs, including TARO-VALSARTAN, with other agents blocking the RAS such as ACEIs or aliskiren-containing drugs is not recommended in any patient, as adverse outcomes cannot be excluded.
Driving and Operating Machinery Exercise caution when driving or operating a vehicle or potentially dangerous machinery. Hepatic/Biliary/Pancreatic On average, patients with mild to moderate chronic liver disease have twice the exposure to valsartan of healthy volunteers as measured by AUC and Cmax.
3 Pharmacokinetics). Renal As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death.
In susceptible patients, concomitant diuretic use may further increase risk. Following myocardial infarction, major renal dysfunction was observed to occur more frequently with valsartan than with captopril monotherapy (see 8 ADVERSE REACTIONS - Following Myocardial Infarction).
The role of modestly lower blood pressure that may occur with valsartan compared to captopril monotherapy is not known. 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 10 of 45 Quantitative Data).
Patients exposed to potassium-sparing diuretics and/or potassium supplements were more likely to develop hyperkalemia. Accordingly, their use should be carefully monitored or avoided (see
1 Special Populations ....................................................................................................... 1 Pregnant Women: ......................................................................................................
2 Breast-feeding:........................................................................................................... 3 Pediatrics ...................................................................................................................
4 Geriatrics ................................................................................................................... 11 8. 2 Clinical Trial Adverse Reactions .....................................................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ............................................................................................................................. 14 9. 1 Serious Drug Interactions ..............................................................................................
4 Drug-Drug Interactions.................................................................................................. 5 Drug-Food Interactions .................................................................................................
1 Mechanism of Action ............................................................................................... 2 Pharmacodynamics..................................................................................................
1 Clinical Trials by Indication ....................................................................................... 32 17 SUPPORTING PRODUCT MONOGRAPHS. 38 PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 4 of 45 PART I: HEALTH PROFESSIONAL INFORMATION 1.
INDICATIONS TARO-VALSARTAN (valsartan tablets) is indicated for: • Hypertension o For the treatment of mild to moderate essential hypertension. o TARO-VALSARTAN may be administered alone, or concomitantly with thiazide diuretics. o The safety and efficacy of concurrent treatment with valsartan and angiotensin converting enzyme inhibitors have not been established.
• Following Myocardial Infarction o To reduce cardiovascular mortality in clinically […]
In patients whose blood pressure is not adequately controlled, the daily dose may be increased to a maximum of 320 mg or a thiazide diuretic added. It is not recommended to prescribe the maximum dose of 320 mg without prior up-titration.
3 Pharmacokinetics). • Following Myocardial Infarction TARO-VALSARTAN may be initiated as early as 12 hours after a myocardial infarction in clinically stable patients. In order to diminish the risk of hypotension, the recommended starting dose is 20 mg twice daily.
Thereafter, patients may be up titrated within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dose of 160 mg twice daily, as tolerated. If symptomatic hypotension or renal dysfunction occurs, consideration should be given to dosage reduction.
TARO-VALSARTAN should be given with other standard post-myocardial infarction treatment, including thrombolytics, aspirin and statins, as indicated. Concomitant use of beta-blockers is to be encouraged with TARO-VALSARTAN in this clinical setting, if indicated, since further substantial relative risk reduction may be expected with such use over that of valsartan alone.
• Heart Failure The recommended starting dose of TARO-VALSARTAN is 40 mg twice daily. Titration every two weeks to 80 mg and 160 mg twice daily should be done to the highest dose tolerated by the patient. Consideration should be given to reduce the dose of concomitant diuretics.
The maximum recommended dose is 160 mg twice daily. 5 Missed Dose Patients should try to take their dose at the same time each day, preferably in the morning. However, if they have forgotten to take the dose during the day, they should carry on with the next dose at the usual time.
They should not double doses. 5. OVERDOSAGE Limited data are available in regard to overdosage with valsartan in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
Depressed level of consciousne ss, circulatory PrTARO-VALSARTAN (Valsartan Tablets) Product Monograph Page 7 of 45 collapse and shock have been reported. If symptomatic hypotension should occur, supportive treatment should be instituted.
Valsartan is not removed from the plasma by dialysis. For management of a suspected drug overdose, contact your regional poison control centre. 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1 – Dosage Forms, Strengths, Composition and Packaging Route of Administration Dosage Form / Strength/Composition Non-medicinal Ingredients Oral Tablets 40 mg, 80 mg and 160 mg Crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, silica colloidal anhydrous, talc and titanium dioxide.
Additionally, the 40 mg tablet contains iron oxide yellow; the 80 mg tablet contains iron oxide black and iron oxide red; and the 160 mg tablet contains iron oxide red and iron oxide yellow. Description TARO-VALSARTAN 40 mg tablets TARO-VALSARTAN tablets, 40 mg are yellow coloured, film-coated, oval-shaped tablets with beveled edges, debossed with V & 4 on either side of breakline on one side and plain on the other side.
TARO-VALSARTAN 40 mg tablets are supplied in bottles of 100 tablets and blisters of 10 tablets. Since the 40 mg tablets are scored on one side, these may be used to initiate therapy following myocardial infarction (see